CN108721572B - A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis - Google Patents
A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis Download PDFInfo
- Publication number
- CN108721572B CN108721572B CN201810957513.XA CN201810957513A CN108721572B CN 108721572 B CN108721572 B CN 108721572B CN 201810957513 A CN201810957513 A CN 201810957513A CN 108721572 B CN108721572 B CN 108721572B
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- traditional chinese
- liver cancer
- liver cirrhosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 50
- 201000007270 liver cancer Diseases 0.000 claims abstract description 41
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 41
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 18
- 241000132012 Atractylodes Species 0.000 claims abstract description 16
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 13
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 13
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 13
- 210000002826 placenta Anatomy 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 12
- 235000008671 Calycanthus floridus Nutrition 0.000 claims abstract description 11
- 235000008670 Calycanthus occidentalis Nutrition 0.000 claims abstract description 11
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 11
- 244000148992 Lindera benzoin Species 0.000 claims abstract description 11
- 235000004520 Lindera benzoin Nutrition 0.000 claims abstract description 11
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 claims abstract description 11
- 241000208682 Liquidambar Species 0.000 claims abstract description 11
- 235000006552 Liquidambar styraciflua Nutrition 0.000 claims abstract description 11
- 241000545744 Hirudinea Species 0.000 claims abstract description 9
- 241000283966 Pholidota <mammal> Species 0.000 claims abstract description 9
- 241000427159 Achyranthes Species 0.000 claims abstract description 8
- 241000915604 Scutellaria barbata Species 0.000 claims abstract description 8
- 210000003038 endothelium Anatomy 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 7
- 241000131329 Carabidae Species 0.000 claims description 6
- 241000756943 Codonopsis Species 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 240000000031 Achyranthes bidentata Species 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 241001489978 Eupolyphaga Species 0.000 claims description 4
- 241000237903 Hirudo Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 241000283956 Manis Species 0.000 claims description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 240000003146 Lobelia chinensis Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 3
- 241000347881 Kadua laxiflora Species 0.000 claims description 2
- 244000080767 Areca catechu Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 18
- 210000004185 liver Anatomy 0.000 abstract description 13
- 210000000952 spleen Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 230000003908 liver function Effects 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 244000197580 Poria cocos Species 0.000 abstract description 3
- 235000008599 Poria cocos Nutrition 0.000 abstract description 3
- 241000301400 Trogopterus Species 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000035619 diuresis Effects 0.000 abstract description 3
- 230000004792 oxidative damage Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 241000045403 Astragalus propinquus Species 0.000 abstract description 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 2
- 235000006533 astragalus Nutrition 0.000 abstract description 2
- 210000003608 fece Anatomy 0.000 abstract description 2
- 241001489980 Eupolyphaga sinensis Species 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 10
- 241000202755 Areca Species 0.000 description 8
- 102000003952 Caspase 3 Human genes 0.000 description 8
- 108090000397 Caspase 3 Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000018832 Cytochromes Human genes 0.000 description 5
- 108010052832 Cytochromes Proteins 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 101710170789 Protein bax Proteins 0.000 description 4
- 230000006909 anti-apoptosis Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 101710117545 C protein Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 208000007348 Experimental Liver Cirrhosis Diseases 0.000 description 2
- 241001427555 Polyphaga <Blattaria> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000723363 Clerodendrum Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Insects & Arthropods (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating liver cancer and liver cirrhosis, which comprises 21 traditional Chinese medicinal materials of eupolyphaga sinensis Walker, leech, pangolin scales, endothelium corneum gigeriae galli, human placenta, codonopsis pilosula, astragalus membranaceus, poria cocos, pseudo-ginseng, radix curcumae, bighead atractylodes rhizome, oldenlandia diffusa, hairyvein agrimony, barbed skullcap herb, achyranthes root, pericarpium arecae, combined spicebush root, rhizoma atractylodis, gardenia, beautiful sweetgum fruit and trogopterus dung. The traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis, strengthening spleen and tonifying qi, clearing heat and removing toxicity, eliminating dampness and promoting diuresis, warming and invigorating spleen and kidney and the like, and has a remarkable treatment effect on liver cancer and liver cirrhosis. Animal experiments and clinical application show that the medicine has obvious anti-hepatic fibrosis effect; can obviously improve liver function and enhance the capability of the liver for resisting oxidative damage; can stabilize tumor body and inhibit liver cancer development; can improve the life quality of patients and obviously prolong the life cycle of patients.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating liver cancer and liver cirrhosis.
Background
Liver cancer is one of common malignant tumors in China, and new cancer cases in China are the first in the world. The human body is an organic whole, and although the curative effect of treating liver cancer in western medicine is obvious, the method mainly aims at local treatment of focus, and most of the method has toxic and side effects. Particularly for patients with advanced liver cancer or liver cancer accompanied with liver cirrhosis, western medicine treatment is often stranded. Emphasizes the characteristics of small toxic and side effects and good curative effect of the traditional Chinese medicine in the aspects of overall regulation, strengthening body resistance to eliminate pathogenic factors, regulating balance and improving immunity, can make up the defects of western medicine, makes a great breakthrough in the treatment of liver cancer and liver cirrhosis and brings good news to patients.
According to traditional Chinese medicine, liver cancer belongs to the categories of tympanites, jaundice, liver stagnation, abdominal masses and the like in traditional Chinese medicine, the names of diseases in modern traditional Chinese medicine are collectively called liver cancer disease, and the liver cancer is divided into the following five symptoms: liver stagnation and spleen deficiency, damp-heat of liver and gallbladder, blood stasis due to liver heat, damp-encumbering due to spleen deficiency, and yin deficiency of liver and kidney. The main symptoms are qi and blood deficiency of viscera, spleen deficiency, dampness accumulation, phlegm coagulation and blood stasis; invasion of six excesses by pathogenic toxin, pathogenic coagulation and accumulation, seven emotions internal injury, emotional depression and the like cause qi, blood, dampness, heat, stasis and toxin to be combined to form liver cancer, and the main pathogenesis is that vital qi is deficient in the interior and pathogenic toxin is accumulated.
According to the common identification of the traditional Chinese medicine and western medicine for treating the liver cirrhosis, the liver cirrhosis is divided into 6 syndrome types: water-damp internal resistance type, spleen-kidney yang deficiency type, blood stasis collateral obstruction type, liver qi stagnation type, damp-heat accumulation type, and liver-kidney yin deficiency type.
Therefore, the traditional Chinese medicine with the effects of promoting blood circulation to remove blood stasis, strengthening spleen and replenishing qi, clearing heat and detoxicating, eliminating dampness and promoting diuresis, warming and invigorating spleen and kidney and the like is widely applied to clinical treatment of liver cancer and liver cirrhosis, and has obvious effect.
The invention relates to a traditional Chinese medicine composition, which consists of 21 traditional Chinese medicines. In the formula, the oldenlandia diffusa, the agrimony, the sculellaria barbata, the achyranthes bidentata, the areca peel, the combined spicebush root, the rhizoma atractylodis, the gardenia, the sweetgum fruit, the trogopterus dung-worm and the bighead atractylodes rhizome have the effects of clearing away heat and toxic materials, eliminating dampness and promoting diuresis, and warming and invigorating spleen and kidney; eupolyphaga Seu Steleophaga, Hirudo, squama Manis, endothelium corneum Gigeriae Galli, placenta hominis, radix Codonopsis, radix astragali, Poria, Notoginseng radix and radix Curcumae have effects of promoting blood circulation for removing blood stasis, invigorating spleen and invigorating qi. The compatibility of the medicine composition accords with the treatment rules of liver cancer and liver cirrhosis, and is mainly used for treating liver cancer and liver cirrhosis, particularly patients with advanced liver cancer and liver cirrhosis.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition with remarkable treatment effect on liver cancer and liver cirrhosis.
The traditional Chinese medicine composition for treating liver cancer and liver cirrhosis comprises the following traditional Chinese medicine raw materials in parts by weight: 90-100 parts of oldenlandia diffusa, 90-100 parts of hairyvein agrimony, 90-100 parts of sculellaria barbata, 45-55 parts of achyranthes bidentata, 45-55 parts of pericarpium arecae, 30-40 parts of radix linderae, 90-95 parts of rhizoma atractylodis, 30-35 parts of fructus gardeniae, 30-40 parts of fructus liquidambaris, 150-170 parts of radix aconiti szechenyiani, 90-105 parts of rhizoma atractylodis macrocephalae, 3-5 parts of ground beetle, 2-5 parts of leech, 2-4 parts of pangolin scales, 3-5 parts of endothelium corneum gigeriae galli, 4-5 parts of human placenta, 2-5 parts of codonopsis pilos.
According to the preferred scheme of the traditional Chinese medicine composition for treating liver cancer and liver cirrhosis, the weight parts of the raw materials are as follows: 90 parts of oldenlandia diffusa, 90 parts of hairyvein agrimony, 90 parts of barbed skullcap herb, 45 parts of twotooth achyranthes root, 45 parts of areca peel, 30 parts of combined spicebush root, 90 parts of swordlike atractylodes rhizome, 30 parts of cape jasmine fruit, 30 parts of beautiful sweetgum fruit, 150 parts of Chinese lobelia herb, 90 parts of largehead atractylodes rhizome, 3 parts of ground beetle, 2 parts of leech, 2 parts of pangolin scales, 3 parts of chicken's gizzard-membrane, 4.5 parts of human placenta, 3.
The traditional Chinese medicine composition for treating liver cancer and liver cirrhosis can be prepared into tablets, granules, dispersible tablets, capsules, pills, soft extracts, mixtures and water-honeyed pills.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating liver cancer and liver cirrhosis.
The preparation method of the traditional Chinese medicine composition for treating liver cancer and liver cirrhosis comprises the following steps:
(1) crushing medicinal materials: pulverizing Eupolyphaga Seu Steleophaga, Hirudo, squama Manis, endothelium corneum Gigeriae Galli, placenta hominis, radix Codonopsis, radix astragali, Poria, Notoginseng radix and radix Curcumae into fine powder;
(2) the preparation method comprises the steps of taking oldenlandia diffusa, agrimony, barbed skullcap herb, twotooth achyranthes root, areca peel, combined spicebush root, rhizoma atractylodis, cape jasmine fruit, beautiful sweetgum fruit, five-claw dragon and largehead atractylodes rhizome according to the weight parts, adding water for 2 times, wherein the water amount added in each time is 12 times of the total weight of the medicinal materials, and the decocting time is 1.5 hours. Filtering, and concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.07-1.25 (measured at 25 deg.C);
(3) mixing the fine powder obtained in step (1) with the fluid extract obtained in step (2), drying under reduced pressure, pulverizing into fine powder, sieving, and making into corresponding dosage forms such as capsule, water-honeyed pill, soft extract, tablet and granule according to various dosage forms and adjuvants; or preparing the fine powder obtained in the step (1) into a solid preparation, and preparing the clear paste obtained in the step (2) into a liquid preparation, and taking the two preparations in a matching way.
Animal experiments and clinical application show that the traditional Chinese medicine composition for treating liver cancer and liver cirrhosis has an obvious anti-hepatic fibrosis effect; can obviously improve liver function and enhance the capability of the liver for resisting oxidative damage; can stabilize tumor body and inhibit liver cancer development; can improve the life quality of patients and obviously prolong the life cycle of patients.
Drawings
FIG. 1 Effect of Chinese medicinal composition on tumor size of H22 hepatoma bearing mice
FIG. 2 shows the effect of the Chinese medicinal composition on apoptosis-related protein in tumor tissue of H22 hepatoma bearing mice
(1) FIG. 2 is a protein band diagram in mouse tumor tissue, the deeper the protein band, the more the protein expression (based on the overall protein quantification, i.e. under the condition of consistent internal reference GAPDH band), and the measured indicators include: pro-apoptotic protein Bax, anti-apoptotic protein Bcl-2, cytochrome C (Cyt-C), Caspase3, and their activated forms, clear Caspase-3.
(2) The apoptosis-promoting protein Bax and the anti-apoptosis protein Bcl-2 can influence mitochondria to release cytochrome C (Cyt-C), and further activate Caspase family activation, so that the execution death factor Caspase3 is activated into cleared Caspase-3, and finally tumor cells are apoptotic.
The band of fig. 2 shows that the traditional Chinese medicine composition can improve the content of apoptosis-promoting protein Bax and cytochrome C protein, reduce the content of anti-apoptosis protein Bcl-2, increase the activation amount of cleared caspase-3, increase the apoptosis of tumor tissues by influencing the apoptosis pathway and inhibit the development of liver cancer.
Detailed Description
The present invention will be described in further detail with reference to specific examples, but the scope of the present invention as claimed is not limited to the following examples.
Example 1
A traditional Chinese medicine composition for treating liver cancer and liver cirrhosis is composed of the following components in parts by weight: 90 parts of oldenlandia diffusa, 90 parts of hairyvein agrimony, 90 parts of barbed skullcap herb, 45 parts of twotooth achyranthes root, 45 parts of areca peel, 30 parts of combined spicebush root, 90 parts of swordlike atractylodes rhizome, 30 parts of cape jasmine fruit, 30 parts of beautiful sweetgum fruit, 150 parts of Chinese lobelia herb, 90 parts of largehead atractylodes rhizome, 3 parts of ground beetle, 2 parts of leech, 2 parts of pangolin scales, 3 parts of chicken's gizzard-membrane, 4.5 parts of human placenta, 3.
Example 2
A traditional Chinese medicine composition for treating liver cancer and liver cirrhosis is composed of the following components in parts by weight: 95 parts of oldenlandia diffusa, 95 parts of hairyvein agrimony, 95 parts of barbed skullcap herb, 45 parts of twotooth achyranthes root, 45 parts of areca peel, 30 parts of combined spicebush root, 90 parts of rhizoma atractylodis, 30 parts of cape jasmine fruit, 30 parts of beautiful sweetgum fruit, 150 parts of dragon's blood, 95 parts of largehead atractylodes rhizome, 4 parts of ground beetle, 3 parts of leech, 3 parts of pangolin scales, 3.5 parts of chicken's gizzard-membrane, 4.5 parts of human placenta, 3 parts of pilose.
Example 3
Weighing 90 parts of spreading hedyotis herb, 90 parts of hairyvein agrimony, 90 parts of barbed skullcap herb, 45 parts of twotooth achyranthes root, 45 parts of areca peel, 30 parts of combined spicebush root, 90 parts of swordlike atractylodes rhizome, 30 parts of cape jasmine fruit, 30 parts of beautiful sweetgum fruit, 150 parts of five-claw dragon and 90 parts of largehead atractylodes rhizome. One dose is taken every day, 3 times a day, and the decoction is taken. Weighing 3 portions of Chinese polyphaga, 2 portions of leech, 2 portions of pangolin scales, 3 portions of chicken's gizzard-membrane, 4.5 portions of human placenta, 3 portions of radix codonopsitis, 3 portions of astragalus root, 3 portions of tuckahoe, 3 portions of notoginseng and 3 portions of radix curcumae 3 according to the weight portion, mixing and grinding the mixture into powder twice a day, and taking the powder with boiled water.
Example 4
A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis is prepared into capsule and oral liquid by the following steps.
(1) According to the first weight part of the embodiment, the Chinese polyphaga, the leech, the pangolin scales, the endothelium corneum gigeriae galli, the human placenta, the codonopsis pilosula, the astragalus membranaceus, the poria cocos, the pseudo-ginseng and the radix curcumae are taken, crushed and sieved, so that the powder can completely pass through a 65-mesh sieve, the powder which can pass through a 80-mesh sieve is not more than 60 percent, the mixture is dried in a vacuum drying oven (-0.04 to-0.06 Mpa at 75 ℃) to constant weight, and the;
(2) according to the embodiment, according to the weight parts, oldenlandia diffusa, agrimony, sculellaria barbata, achyranthes bidentata, areca peel, combined spicebush root, rhizoma atractylodis, gardenia, beautiful sweetgum fruit, trogopterus dung and bighead atractylodes rhizome are taken, water is added for extraction for 2 times, the water amount added for each time is 12 times of the total mass of the medicinal materials, and the extraction time for each time is 1.5 hours. Filtering, combining filtrates, centrifuging to remove impurities, taking supernatant, concentrating under reduced pressure (60 ℃) to obtain clear paste with the relative density of 1.07-1.30 (measured at 25 ℃), cooling, adding 6% of aspartame, 0.25% of sodium benzoate and 0.05% of ethylparaben, stirring uniformly, filling and sterilizing to obtain the product.
Example 5
A Chinese medicinal composition for treating liver cancer and liver cirrhosis is prepared into tablets according to the following formula and steps:
(1) crushing medicinal materials: pulverizing Eupolyphaga Seu Steleophaga, Hirudo, squama Manis, endothelium corneum Gigeriae Galli, placenta hominis, radix Codonopsis, radix astragali, Poria, Notoginseng radix and radix Curcumae into fine powder;
(2) according to the second embodiment, the oldenlandia diffusa, the agrimony, the sculellaria barbata, the achyranthes bidentata, the areca peel, the combined spicebush root, the rhizoma atractylodis, the gardenia, the beautiful sweetgum fruit, the cairo glorybower herb and the bighead atractylodes rhizome are taken according to the parts by weight, water is added for 2 times, the water amount is 12 times of the total mass of the medicinal materials, and the extraction time is 1.5 hours. Filtering, combining filtrates, centrifuging to remove impurities, taking supernatant, and concentrating under reduced pressure to obtain fluid extract with relative density of 1.07-1.30 (measured at 25 ℃);
(3) mixing the fine powder obtained in step (1) with the fluid extract obtained in step (2), drying under reduced pressure, pulverizing into fine powder, sieving, adding appropriate adjuvant, granulating, and tabletting.
Example 6
A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis can be made into other dosage forms.
For example, after mixing the fine powder obtained in the step (1) and the clear paste obtained in the step (2) in the example 5, drying under reduced pressure, adding proper auxiliary materials for granulation, and obtaining granules; or mixing the fine powder obtained in the step (1) and the clear paste obtained in the step (2) in the embodiment 5, and adding refined honey or sugar to obtain the soft extract.
Example 7
Experiment on treatment effect of traditional Chinese medicine composition on experimental liver cirrhosis rats
Materials (I) and (II)
1. Medicine preparation: the drug was formulated as in example 1.
2. Animals: SD rats, SPF grade, male, body weight (200 ± 20) g, provided by the animal testing center of the university of pharmaceutical, guangxi.
Second, Experimental methods
Selecting 72 SPF male SD rats, randomly selecting 11 rats, adding into solvent control group, and administering equal volume of purified water, wherein the volume of the rest rats is 2 mL/kg-1Intragastric perfusion of 50% CCl4Olive oil was used 2 times a week for 8 weeks to establish a cirrhosis model. The 55 model rats were randomly divided into 5 groups, model group, drug low, medium and high dose groups (5.4, 10.8, 21.5g crude drug/kg)-1) Carapax Trionycis liver softening tablet set (0.8g kg)-1) 11 per group. According to 10 mL/kg-1Administration phase by intragastric administrationThe liquid medicine, the solvent group and the model group are administrated with purified water with equal volume, and the administration is performed for 4 weeks after intragastric administration for 1 time respectively in the morning and afternoon of a day. Before the last administration, fasting is carried out for 12 h-16 h without water prohibition, and after the last administration, the dose is 3 mL/kg-1Intraperitoneal injection of 10% chloral hydrate for anesthesia, abdominal aorta blood sampling, 4000 rmp.min-1Centrifuging for 10min, collecting serum to measure liver function index and hepatic fibrosis index, and collecting liver tissue of the same part to measure antioxidant capacity index levels such as SOD and MDA.
Third, experimental results
The results are shown in tables 1, 2 and 3.
TABLE 1 Chinese medicinal composition for CCl4Effect of liver function in rats causing liver cirrhosis
Note: in comparison with the set of models,1)P<0.05,2)P<0.01。
TABLE 2 Chinese medicinal composition for CCl4Effect of hepatic fibrosis level in rats with liver cirrhosis
Note: in comparison with the set of models,1)P<0.05,2)P<0.01。
TABLE 3 Chinese medicinal composition for CCl4Influence of liver tissue antioxidant index of rat with liver cirrhosis
Note: in comparison with the set of models,1)P<0.05,2)P<0.01。
the experimental results show that the traditional Chinese medicine composition can obviously improve the liver function of experimental liver cirrhosis rats, enhance the capability of the liver for resisting fibrosis formation and improve the oxidation resistance of the liver.
Example 8
Anti-tumor effect experiment of traditional Chinese medicine composition on mouse H22 liver cancer transplantation tumor
Materials (I) and (II)
1. Medicine preparation: the drug was formulated as in example 2.
2. Animals: KM mice, 22-25 g, male, were provided by the laboratory animal center of Guangxi medical university.
3. Tumor strain: provided by the pharmacological research laboratory at the university of medical science, Guangxi and subcultured.
Second, Experimental methods
Killing mice inoculated with H22 ascites tumor with obvious abdominal bulge for 9 days by cervical dislocation, extracting tumor liquid from abdominal cavity under aseptic condition, diluting with aseptic normal saline, and 800 rmp.min-1Centrifuging for 5min, removing supernatant to obtain tumor cells, and adding physiological saline to adjust tumor cell concentration to 1 × 107Mice were inoculated subcutaneously in the right axilla at this concentration with tumor cell suspension at 0.2 mL/mL (except for the normal group). Weighing 60 mice 24 hours after inoculation, and inoculating 10 non-inoculated mice into a normal group; the remaining 50 were randomly divided into 5 groups: the medicine has low, medium and high dosage (13.9, 27.7, 55.4g crude drug/kg)-1) Group (d); cyclophosphamide group (20mg kg)-1) And model control groups of 10 animals each. The dosage of the composition is 20 ml/kg-1Performing intragastric administration in volume, and performing once every morning and afternoon; equal volume of the normal saline is used for the model control group; the cyclophosphamide group is administered by intraperitoneal injection with a dosage volume of 20m1 kg-1Every two days. After continuous administration for 10 days, blood is taken from eyeballs for killing, thymus, spleen and tumor are picked, weight is weighed, and tumor inhibition rate, spleen index and thymus index are calculated. Tumor inhibition rate ═ (mean tumor weight model group-mean tumor weight administered group)/mean tumor weight model group × 100%; spleen or thymus index-spleen (thymus) weight mg/body weight g × 10.
Third, experimental results
The results are shown in tables 4 and 5.
TABLE 4 influence of the Chinese medicinal composition on the body weight, thymus index and spleen index of H22 hepatocarcinoma tumor-bearing mice
Note: in comparison with the set of models,1)P<0.05,2)P<0.01。
TABLE 5 influence of the Chinese medicinal composition on tumor weight and tumor inhibition rate of mouse liver cancer transplantable tumor
Note: in comparison with the set of models,1)P<0.05,2)P<0.01。
the result shows that the tumor inhibition rate of the traditional Chinese medicine composition administration group to the H22 liver cancer transplantation tumor can reach 47.39%, which shows that the traditional Chinese medicine composition has obvious inhibition effect on experimental liver cancer (see the attached figure 1 of the specification).
In addition, indexes of apoptosis-promoting protein Bax, anti-apoptosis protein Bcl-2, cytochrome C (Cyt-C), Caspase3 and activated form thereof, such as cleaned Caspase-3, in tumor tissues are measured, and results show that the traditional Chinese medicine composition can improve the contents of the apoptosis-promoting protein Bax and the cytochrome C protein, reduce the content of the anti-apoptosis protein Bcl-2, increase the activated amount of the cleaned Caspase-3, increase tumor tissue apoptosis by influencing an apoptosis pathway and inhibit the development of liver cancer (see the attached figure 2 of the specification).
Example 9
Patients of Huangxxx, male, 58 years old, Guangxi Nanning people, liver and gall surgery diagnosis of tumor hospital of Guangxi medical university shows that liver cancer is late with ascites due to cirrhosis, and the life cycle is predicted to be 6 months. After the patient abandons the treatment and is discharged from hospital, the patient takes the traditional Chinese medicine composition of the third embodiment to treat the disease. After the medicine is taken for half a year, the re-examination finds that the hepatoma tumor mass is reduced, the ascites is eliminated and the liver function is gradually improved. The patient also returned from the initial bedridden condition to simple housework. After the medicine is continuously taken for half a year, the daily life of the patient is recovered, and simple agricultural labor can be carried out. The proved recipe prolongs the life of the patient by 2 years.
Patients with Liu XXx, male and 48 years old suffer from liver cirrhosis, dry and rough skin, gray and dark complexion, vomiting and diarrhea, even bedridden, have improved spirit after half a month of continuous treatment, obviously inhibit the state of the illness after 3 months, do daily housework, and normally live at diet and normally carry out agricultural labor during the period of continuing taking the medicine.
In conclusion, the traditional Chinese medicine composition for treating liver cancer and liver cirrhosis has obvious effects of resisting liver fibrosis formation, improving liver functions and enhancing the capacity of resisting oxidative damage of the liver; can stabilize tumor body, promote tumor tissue apoptosis, and inhibit liver cancer development; improve the life quality of the patients and obviously prolong the life cycle of the patients.
Claims (4)
1. A traditional Chinese medicine composition for treating liver cancer and liver cirrhosis is composed of the following 21 traditional Chinese medicines in parts by weight: 90-100 parts of oldenlandia diffusa, 90-100 parts of hairyvein agrimony, 90-100 parts of sculellaria barbata, 45-55 parts of achyranthes bidentata, 45-55 parts of pericarpium arecae, 30-40 parts of radix linderae, 90-95 parts of rhizoma atractylodis, 30-35 parts of fructus gardeniae, 30-40 parts of fructus liquidambaris, 150-170 parts of radix aconiti szechenyiani, 90-105 parts of rhizoma atractylodis macrocephalae, 3-5 parts of ground beetle, 2-5 parts of leech, 2-4 parts of pangolin scales, 3-5 parts of endothelium corneum gigeriae galli, 4-5 parts of human placenta, 2-5 parts of codonopsis pilos.
2. The traditional Chinese medicine composition for treating liver cancer and liver cirrhosis according to claim 1, wherein the traditional Chinese medicine comprises the following raw materials in parts by weight: 90 parts of oldenlandia diffusa, 90 parts of hairyvein agrimony, 90 parts of barbed skullcap herb, 45 parts of twotooth achyranthes root, 45 parts of areca peel, 30 parts of combined spicebush root, 90 parts of swordlike atractylodes rhizome, 30 parts of cape jasmine fruit, 30 parts of beautiful sweetgum fruit, 150 parts of Chinese lobelia herb, 90 parts of largehead atractylodes rhizome, 3 parts of ground beetle, 2 parts of leech, 2 parts of pangolin scales, 3 parts of chicken's gizzard-membrane, 4.5 parts of human placenta, 3.
3. The Chinese medicinal composition for treating liver cancer and liver cirrhosis according to claim 1, which is prepared into tablets, granules, capsules, pills, soft extract or mixture.
4. The preparation method of the Chinese medicinal composition for treating liver cancer and liver cirrhosis according to claim 2, comprising the following steps:
(1) crushing medicinal materials: pulverizing Eupolyphaga Seu Steleophaga, Hirudo, squama Manis, endothelium corneum Gigeriae Galli, placenta hominis, radix Codonopsis, radix astragali, Poria, Notoginseng radix and radix Curcumae into fine powder;
(2) taking oldenlandia diffusa, hairyvein agrimony, barbed skullcap herb, twotooth achyranthes root, areca peel, combined spicebush root, swordlike atractylodes rhizome, cape jasmine fruit, beautiful sweetgum fruit, five-claw dragon and largehead atractylodes rhizome according to the parts by weight, adding water for 2 times, wherein the water amount is 12 times of the total mass of the medicinal materials each time, the decocting time is 1.5 hours each time, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.07-1.25 at 25 ℃;
(3) mixing the fine powder obtained in step (1) and the fluid extract obtained in step (2), drying under reduced pressure, pulverizing into fine powder, sieving, and making into capsule, pill, soft extract, tablet or granule according to dosage form process and adjuvant requirement.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810957513.XA CN108721572B (en) | 2018-08-21 | 2018-08-21 | A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810957513.XA CN108721572B (en) | 2018-08-21 | 2018-08-21 | A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108721572A CN108721572A (en) | 2018-11-02 |
CN108721572B true CN108721572B (en) | 2021-05-07 |
Family
ID=63941645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810957513.XA Expired - Fee Related CN108721572B (en) | 2018-08-21 | 2018-08-21 | A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108721572B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1582995A (en) * | 2004-06-15 | 2005-02-23 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
CN103041015A (en) * | 2012-12-29 | 2013-04-17 | 南宁多灵生物科技有限公司 | Medicine for treatment of hepatitis |
-
2018
- 2018-08-21 CN CN201810957513.XA patent/CN108721572B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1582995A (en) * | 2004-06-15 | 2005-02-23 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
CN103041015A (en) * | 2012-12-29 | 2013-04-17 | 南宁多灵生物科技有限公司 | Medicine for treatment of hepatitis |
Non-Patent Citations (1)
Title |
---|
原发性肝癌治验;杨秀静等;《山东中医杂志》;20120905;第31卷(第09期);681-682 * |
Also Published As
Publication number | Publication date |
---|---|
CN108721572A (en) | 2018-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
CN107693571B (en) | Traditional Chinese medicine composition and preparation for preventing or treating hepatic fibrosis and liver cirrhosis and preparation method of preparation | |
CN1250275C (en) | Traditional Chinese medicine for treating cancer and preparation method thereof | |
CN101129720B (en) | Compound medicament for treating ankylosing spondylitis | |
CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
CN103142841B (en) | Traditional Chinese medicine composition for treating osteonecrosis of femoral head | |
CN108721572B (en) | A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis | |
CN103768349B (en) | Application in preparation treatment cerebrovascular and relevant disease medicine for the four taste Fructus cinnamomi camphorae preparations | |
CN106334171A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof | |
CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
CN101020002B (en) | Compound Chinese medicine preparation for assisting tumor radiotherapy and its preparation method | |
CN100475248C (en) | A medicine for treating metrorrhagia and preparation process thereof | |
CN114272349A (en) | Traditional Chinese medicine composition for tonifying spleen and nourishing liver and preparation method and application thereof | |
CN114404547B (en) | Body resistance strengthening and blood stasis removing cream formula and application thereof | |
CN1319411A (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
CN106729101B (en) | Traditional Chinese medicine composition for treating post-circulation ischemic stroke and preparation method thereof | |
CN104645247A (en) | Traditional Chinese medicine preparation for treating hepatolenticular degeneration and preparation method of traditional Chinese medicine preparation | |
CN104491602A (en) | Traditional Chinese medicine for treating chronic heart failure, premature beat and arrhythmia and preparation method thereof | |
CN113209251A (en) | Traditional Chinese medicine composition, preparation method and application of traditional Chinese medicine composition in preparation of antitumor drugs | |
CN116549583A (en) | Traditional Chinese medicine composition for ascending, removing stasis and dissolving turbidity as well as preparation method and application thereof | |
CN114617939A (en) | Traditional Chinese medicine preparation for treating cerebral arterial thrombosis | |
CN100342902C (en) | Anti-cancer drug and process for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210507 |
|
CF01 | Termination of patent right due to non-payment of annual fee |